

National Institute for Health & Clinical Excellence

Hyperglycaemia Short Clinical Guideline

Guideline Development Group (GDG) meeting one

1st GDG Meeting – 30th November & 1st December 2010

Dee - Level1a - City Tower – Piccadilly Plaza – Manchester – M1
4BD

GROUP MEMBERSHIP & ACTION LIST

In Attendance	
GDG Members	
Bernard Clarke	Ian Lewin
Lesley Mills	Philip Dyer
Simon Corbett	Steve Williams
Sunil Angris	Dave Peachey
NICE Staff	
Damien Longson (DL)	Victoria Kelly (VK)
Alfred Sackeyfio (AS)	Abitha Senthinathan (ASn)
Laura Norburn (LN)	Stephen Brookfield (SB)
Lynda Ayiku (LA)	Prashanth Kandaswamy (PK)
Rachel Ryle (RR)	Kim Jeong (KJ)
Mark Baker (MB)	

REPORT OF DISCUSSIONS AT THE MEETING

30th November

Introductions & GDG Working

DL asked the group to introduce themselves and discuss their areas of specialty. MB gave a presentation on the key points of GDG methods.

NICE Introductions

NICE staff introduced their areas of work. The presentations covered the following topics; NICE – Overview/SCG & Producing Clinical Guidelines, Timelines, Expenses, Declarations of Interest, Role of the Guidelines Commissioning Manager, Literature Searching , Patient and public Involvement Programme, Costing, Implementation and Health Economics

Summary of the Scope

ASn presented the scope of the guideline to the GDG.

Questionnaire & Responses

AS discussed the results of the pre GDG questionnaire

Agree Definitions

The group discussed the various terms used in the literature and agreed the definitions for use in this guideline

Care Pathway

The group provided the team with the usual pathway of care in treatment of Hyperglycaemia in ACS.

Summary of Day

DL discussed the key points from the day and outlined the agenda for Day 2.

1st December

An introduction to GRADE

AS gave the group a presentation on GRADE and its use in guidance development

Evidence presented and Evidence Summary – Q1

AS presented the evidence to the GDG for the first clinical question on the use of intensive insulin therapy vs standard therapy in patients with hyperglycaemia with a previous diagnosis of diabetes.

Discussion of evidence – Q1

The GDG reviewed the evidence and produced a set of recommendations

Health Economics

KJ gave the group a presentation on the potential areas of economic modelling in this guidance

Next Steps

VK discussed the dates of the next meeting – 24th and 25th March in Manchester